By INS Contributors

MOSCOW, Russia--The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund announces the real-world data of the Ministry of Health of the Republic of San Marino on the Russian Sputnik V vaccine demonstrating it is 80 percent effective against coronavirus infection from 6 th to 8 th months after administering the second dose.

Efficacy of Sputnik V in 6-8 months is much higher than officially published efficacy of mRNA vaccines. Sputnik team believes that adenoviral vaccines provide for longer efficacy than mRNA vaccines due to longer antibody and T-cell response.

The data is based on the number of COVID infections in San Marino in November 2021.

Efficacy was calculated based on data obtained from over 18,600 individuals fully vaccinated with Sputnik V not less than 5 months before November.

The hospitalization rate with COVID infection following vaccination with Sputnik V in San Marino was only 0.75 per 1,000 people during the entire mass vaccination in the country from February to November 2021.

This rate is more than 2 times lower than that of any other vaccine used in the country.

Over 70 percent of the adult population of San Marino have been vaccinated with Sputnik V.

An article published in EClinicalMedicine (an open access clinical journal published by The Lancet, one of the world's most respected medical journals) in July demonstrated that the Russian vaccine has a high safety profile in San Marino.

In particular, Sputnik V shows a high tolerability profile in the ≥60 age group with nearly all reported adverse events following immunization being mild or moderate and lasting less than 2 days.

Sputnik V pioneered the heterogeneous boosting approach (a “vaccine cocktail” using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component).

This approach was proven to be successful in creating a longer and more durable immunity against coronavirus.

Sputnik team offered its booster shot (one-shot Sputnik Light vaccine) to other vaccines to lengthen and strengthen their immune response and took the lead in initiating partnerships around the world to conduct joint studies on the combination of Sputnik Light with vaccines of other producers.

Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors.

RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow.

Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1 tn and covering 95 percent of the regions of the Russian Federation.

RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6 percent of Russia’s GDP.

RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 billion.